IL135964A0 - Adenosine a1 receptor agonists - Google Patents

Adenosine a1 receptor agonists

Info

Publication number
IL135964A0
IL135964A0 IL13596498A IL13596498A IL135964A0 IL 135964 A0 IL135964 A0 IL 135964A0 IL 13596498 A IL13596498 A IL 13596498A IL 13596498 A IL13596498 A IL 13596498A IL 135964 A0 IL135964 A0 IL 135964A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor agonists
agonists
receptor
Prior art date
Application number
IL13596498A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL135964A0 publication Critical patent/IL135964A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13596498A 1997-11-08 1998-11-06 Adenosine a1 receptor agonists IL135964A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
IL135964A0 true IL135964A0 (en) 2001-05-20

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13596498A IL135964A0 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Country Status (29)

Country Link
US (1) US6455510B1 (xx)
EP (2) EP1030857B1 (xx)
JP (1) JP2001522857A (xx)
KR (1) KR20010031875A (xx)
CN (1) CN1285843A (xx)
AP (1) AP2000001801A0 (xx)
AR (1) AR011229A1 (xx)
AT (1) ATE273990T1 (xx)
AU (1) AU2048399A (xx)
BR (1) BR9813976A (xx)
CA (1) CA2309200A1 (xx)
CO (1) CO5021135A1 (xx)
DE (1) DE69825780T2 (xx)
EA (1) EA200000392A1 (xx)
EE (1) EE200000285A (xx)
ES (1) ES2222621T3 (xx)
GB (1) GB9723589D0 (xx)
HR (1) HRP20000275A2 (xx)
HU (1) HUP0004082A2 (xx)
IL (1) IL135964A0 (xx)
IS (1) IS5477A (xx)
MA (1) MA26565A1 (xx)
NO (1) NO20002361L (xx)
PE (1) PE20000013A1 (xx)
PL (1) PL340921A1 (xx)
SK (1) SK6722000A3 (xx)
TR (1) TR200002131T2 (xx)
WO (1) WO1999024449A2 (xx)
ZA (1) ZA9810125B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
DE60315164T2 (de) * 2002-08-15 2008-04-30 CV Therapeutics, Inc., Palo Alto Partielle und volle agonisten von a1-adenosinrezeptoren
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7825126B2 (en) * 2004-09-09 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201001135A1 (ru) * 2008-01-09 2011-02-28 ПиДжиИксХЭЛС ЭлЭлСи Интратекальное лечение невропатической боли агонистами ar
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
IN2012DN01453A (xx) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1457495A1 (en) 2004-09-15
ES2222621T3 (es) 2005-02-01
GB9723589D0 (en) 1998-01-07
EP1030857A2 (en) 2000-08-30
HUP0004082A2 (hu) 2001-04-28
KR20010031875A (ko) 2001-04-16
PE20000013A1 (es) 2000-01-21
TR200002131T2 (tr) 2001-01-22
ATE273990T1 (de) 2004-09-15
DE69825780D1 (de) 2004-09-23
BR9813976A (pt) 2000-09-26
NO20002361D0 (no) 2000-05-05
AP2000001801A0 (en) 2000-06-30
IS5477A (is) 2000-05-03
NO20002361L (no) 2000-07-05
WO1999024449A3 (en) 1999-08-19
EE200000285A (et) 2001-08-15
HRP20000275A2 (en) 2000-12-31
US6455510B1 (en) 2002-09-24
PL340921A1 (en) 2001-03-12
CN1285843A (zh) 2001-02-28
MA26565A1 (fr) 2004-12-20
EP1030857B1 (en) 2004-08-18
WO1999024449A2 (en) 1999-05-20
ZA9810125B (en) 2000-05-05
JP2001522857A (ja) 2001-11-20
DE69825780T2 (de) 2005-01-13
EA200000392A1 (ru) 2000-12-25
SK6722000A3 (en) 2001-01-18
AU2048399A (en) 1999-05-31
CA2309200A1 (en) 1999-05-20
AR011229A1 (es) 2000-08-02
CO5021135A1 (es) 2001-03-27

Similar Documents

Publication Publication Date Title
IL135966A0 (en) Adenosine a1 receptor agonists
IL135965A0 (en) Adenosine a1 receptor agonists
IL135964A0 (en) Adenosine a1 receptor agonists
GB2353527B (en) Adenosine A3 receptor modulators
IL147198A0 (en) N-pyrazole a2a receptor agonists
IL147195A0 (en) C-pyrazole a2a receptor agonists
AU5203999A (en) Beta3-adrenergic receptor agonists
EP0979228A4 (en) CANNABINOID RECEPTOR AGONISTS
AP9801356A0 (en) Prostaglandin agonists
EP1019427A4 (en) N? 6 -SUBSTITUES-ADENOSINE-5'-URONAMIDES USEFUL AS MODULATORS OF ADENOSINE RECEPTORS
EP0980358A4 (en) PHARMACOLGICALLY ACTIVE AGENTS
IL133920A0 (en) Trail receptor
EP0929218A4 (en) R2Y RECEPTOR ANTAGONISTS
IL146471A0 (en) Orally active a1 adenosine receptor agonists
AU4980999A (en) A3 adenosine receptor antagonists
EP1084142A4 (en) GPR35A RECEIVER
EP0973800A4 (en) NEW RECEIVER
EP1036064A4 (en) SELECTIVE BETA 3-ADRENERGIC ANTAGONISTS
GB9819420D0 (en) Novel receptor
EP1092017A4 (en) GABA-B RECEIVER
EP1083909A4 (en) hCEPR RECEPTOR
ZA987267B (en) Nucleosides
IL156852A0 (en) Adenosine a3 receptor modulators
IL156851A0 (en) Adenosine a3 receptor modulators
EP1109565A4 (en) GABAB1AA RECEPTOR